Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Financial and Business Officer
BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases, today announced that Lucinda Warren, who has served as Cue Biopharma’s chief business officer (CBO) since September 2024, has been appointed chief financial and business officer (CFBO) effective February 9, 2026.
“The combination of Lucinda’s financial and business acumen together with her extensive background makes the CFBO a key strategic partner in helping drive business growth and Company success, particularly as we aim to move CUE-401, our lead autoimmune asset, toward the clinic,” said Usman Azam, M.D., president and chief executive officer of Cue Biopharma.
Ms. Warren added, “I am honored to serve Cue Biopharma in this capacity, and I look forward to continuing to support the Company’s corporate priorities and to be a part of this dedicated team.”
Ms. Warren has over 30 years of global experience in the pharmaceutical and biotechnology sectors. Prior to joining Cue Biopharma, she served as vice president of business development for Neuroscience and Japan Regionally at Johnson & Johnson, a healthcare products company, from 2014 to 2024, where she was responsible for end-to-end business development, including licensing, mergers and acquisitions, and alliance management. Her leadership was instrumental in optimizing resources, fostering high-performing teams, and cultivating strong relationships with stakeholders. Ms. Warren’s extensive experience also includes significant roles at Janssen Cilag Australia and Janssen Biologics, where she led business units and managed global transitions, consistently delivering value through strategic transactions. She currently serves as chairman of the board of International School Services, contributing her expertise in finance and governance. Ms. Warren holds a B.S. in biological sciences with a minor in neurology from the University of Alberta.
About Cue Biopharma
Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. The company’s proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system without the adverse effects of broad systemic immune modulation. CUE-401, the company’s lead autoimmune asset, is designed to act mechanistically both as a regulator of proinflammatory mechanisms, and as a master switch for regulatory T cell (Treg) differentiation to induce tolerance. It is a highly innovative, tolerogenic bifunctional molecule combining a TGF-beta breathing-mask moiety with Cue Biopharma’s clinically validated interleukin 2 (IL-2) mutein in a single injectable biologic.
Headquartered in Boston, Massachusetts, we are led by an experienced management team with deep expertise in immunology and protein engineering as well as the design and clinical development of protein biologics.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
$100 Oil Prices Meet AI Computing Hardware Export Boom! Malaysian Ringgit Poised for Forex Comeback with "Dual Catalysts"
Some foreign exchange market strategists believe that, due to rising oil prices and the AI boom, the Malaysian ringgit may strengthen.
Gold tumbles to near $4,200 as hawkish Fed signals and stronger US Dollar pressure bullion
AI demand surges, but the financing "credit gate" is tightening! Under the heavy pressure of the 5% U.S. Treasury yield, compute power losers are gradually emerging
As U.S. Treasury yields rise to their highest levels since 2007, the overall financing cost for AI infrastructure construction is set to become significantly higher. JPMorgan predicts that by 2030, AI-related debt will reach $4.1 trillion.
From Saving Credit Suisse to Considering Cross-border Mergers: UBS (UBS.US) Faces a "Capital Siege", Is the Next Step Joining Forces with Wall Street?
As Switzerland's largest bank faces pressure from stricter capital requirements, several major international banks have approached UBS regarding potential mergers or other collaborations.

